UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants

Vaccine, 2018-10, Vol.36 (45), p.6883-6891

2018

Volltextzugriff (PDF)

Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) in Immunocompromised Adults

The Journal of infectious diseases, 2013-11, Vol.208 (9), p.1375-1385

2013

Volltextzugriff (PDF)

Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants

Human vaccines & immunotherapeutics, 2021-01, Vol.17 (1), p.191-196

2021

Volltextzugriff (PDF)

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

Human vaccines & immunotherapeutics, 2021-08, Vol.17 (8), p.2678-2690

2021

Volltextzugriff (PDF)

Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50—59 Years

Clinical infectious diseases, 2012-04, Vol.54 (7), p.922-928

2012

Volltextzugriff (PDF)

Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants

Human vaccines & immunotherapeutics, 2017-06, Vol.13 (6), p.1352-1358

2017

Volltextzugriff (PDF)

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

Antimicrobial Agents and Chemotherapy, 2008-09, Vol.52 (9), p.3253-3258

2008

Volltextzugriff (PDF)

Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines

Human vaccines & immunotherapeutics, 2019-02, Vol.15 (2), p.426-432

2019

Volltextzugriff (PDF)

Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine

Vaccine, 2018-01, Vol.36 (1), p.179-185

2018

Volltextzugriff (PDF)

Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA™)

Vaccine, 2021-05, Vol.39 (20), p.2764-2771

2021

Volltextzugriff (PDF)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age

Vaccine, 2018-10, Vol.36 (45), p.6875-6882

2018

Volltextzugriff (PDF)

Protective immune responses against Haemophilus influenza type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™)

Vaccine, 2021-03, Vol.39 (9), p.1428-1434

2021

Volltextzugriff (PDF)

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

Clinical and Vaccine Immunology, 2009-09, Vol.16 (9), p.1285-1292

2009

Volltextzugriff (PDF)

Safety and tolerability of zoster vaccine in adults ≥60 years old

Human vaccines, 2011-11, Vol.7 (11), p.1130-1136

2011

Volltextzugriff (PDF)

Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine

The Pediatric infectious disease journal, 2019-04, Vol.38 (4), p.439

2019

Volltextzugriff (PDF)

Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Clinical infectious diseases, 2017-10, Vol.65 (7), p.1174-1182

2017

Volltextzugriff (PDF)

Protective immune responses against Haemophilus influenzae type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™)

Vaccine, 2021-03, Vol.39 (9), p.1428-1434

2021

Volltextzugriff (PDF)

Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults

Vaccine, 2015-06, Vol.33 (24), p.2793-2799

2015

Volltextzugriff (PDF)

Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old

Human vaccines, 2010-11, Vol.6 (11), p.894-902

2010

Volltextzugriff (PDF)

Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older

Clinical and Vaccine Immunology, 2009-05, Vol.16 (5), p.646-652

2009

Volltextzugriff (PDF)

Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies

Vaccine, 2017-03, Vol.35 (14), p.1764-1769

2017

Volltextzugriff (PDF)

Varicella-Zoster Virus-Specific Enzyme-Linked Immunospot Assay Responses and Zoster-Associated Pain in Herpes Zoster Subjects

Clinical and Vaccine Immunology, 2012-09, Vol.19 (9), p.1411-1415

2012

Volltextzugriff (PDF)

A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX

Vaccine, 2019-09, Vol.37 (38), p.5788-5795

2019

Volltextzugriff (PDF)

Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine

The Pediatric infectious disease journal, 2015-02, Vol.34 (2), p.186-194

2015

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(57)

Sprache

Englisch
(57)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants

Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) in Immunocompromised Adults

Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50—59 Years

Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)

Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine

Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA™)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age

Protective immune responses against Haemophilus influenza type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™)

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

Safety and tolerability of zoster vaccine in adults ≥60 years old

Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine

Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Protective immune responses against Haemophilus influenzae type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™)

Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults

Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old

Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older

Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies

Varicella-Zoster Virus-Specific Enzyme-Linked Immunospot Assay Responses and Zoster-Associated Pain in Herpes Zoster Subjects

A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX

Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine

Suchergebnisse filtern